P. Tarshish, J. Tobin, and J. Bernstein, Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children, J Am Soc Nephrol, vol.8, pp.769-776, 1997.

P. Niaudet, Steroid-sensitive idiopathic nephrotic syndrome in children Pediatric Nephrology, pp.543-556, 2004.

H. Kyrieleis, M. Lö-wik, and I. Pronk, Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children, Clinical Journal of the American Society of Nephrology, vol.4, issue.10, pp.1593-1600, 2009.
DOI : 10.2215/CJN.05691108

F. Fakhouri, N. Bocquet, and P. Taupin, Steroid-sensitive nephrotic syndrome: From childhood to adulthood, American Journal of Kidney Diseases, vol.41, issue.3, pp.550-557, 2003.
DOI : 10.1053/ajkd.2003.50116

E. Hodson, N. Willis, and J. Craig, Non-corticosteroid treatment for nephrotic syndrome in children, Cochrane Database Syst Rev, vol.59, issue.2, p.2290, 2008.
DOI : 10.1002/14651858.CD002290.pub3

A. Bagga, P. Hari, and A. Moudgil, Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome, American Journal of Kidney Diseases, vol.42, issue.6, pp.1114-1120, 2003.
DOI : 10.1053/j.ajkd.2003.08.011

H. Kyrieleis, E. Levtchenko, and J. Wetzels, Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome, American Journal of Kidney Diseases, vol.49, issue.5, pp.592-597, 2007.
DOI : 10.1053/j.ajkd.2007.02.270

D. Maloney, A. Grillo-lopez, and C. White, IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non Hodgkin's lymphoma, Blood, vol.90, pp.2188-2195, 1997.

K. Smith, R. Jones, and S. Burns, Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment, Arthritis & Rheumatism, vol.24, issue.9, pp.2970-2982, 2006.
DOI : 10.1002/art.22046

T. Dö-rner, N. Kinnman, and P. Tak, Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers, Pharmacology & Therapeutics, vol.125, issue.3, pp.464-475, 2010.
DOI : 10.1016/j.pharmthera.2010.01.001

G. Remuzzi, C. Chiurchiu, and M. Abbate, Rituximab for idiopathic membranous nephropathy, The Lancet, vol.360, issue.9337, pp.923-924, 2002.
DOI : 10.1016/S0140-6736(02)11042-7

F. Fervenza, F. Cozio, and S. Erickson, Rituximab treatment of idiopathic membranous nephropathy, Kidney International, vol.73, issue.1, pp.117-125, 2008.
DOI : 10.1038/sj.ki.5002628

D. Haffner and D. Fischer, Nephrotic syndrome and rituximab: facts and perspectives, Pediatric Nephrology, vol.354, issue.8, pp.1433-1438, 2009.
DOI : 10.1007/s00467-009-1226-6

V. Guigonis, A. Dallocchio, and V. Baudouin, Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases, Pediatric Nephrology, vol.65, issue.8, pp.1269-1279, 2008.
DOI : 10.1007/s00467-008-0814-1
URL : https://hal.archives-ouvertes.fr/hal-00453355

K. Kamei, S. Ito, and K. Nozu, Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children, Pediatric Nephrology, vol.66, issue.7, pp.1321-1328, 2009.
DOI : 10.1007/s00467-009-1191-0

A. Sellier-leclerc, M. Macher, and C. Loirat, Rituximab efficiency in children with steroid-dependent nephrotic syndrome, Pediatric Nephrology, vol.115, issue.6, pp.1109-1115, 2010.
DOI : 10.1007/s00467-010-1465-6
URL : https://hal.archives-ouvertes.fr/hal-00616352

A. Gulati, A. Sinha, and S. Jordan, Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome: Multicentric Report, Clinical Journal of the American Society of Nephrology, vol.5, issue.12, pp.2207-2212, 2010.
DOI : 10.2215/CJN.03470410

S. Fujinaga, D. Hirano, and N. Nishizaki, Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine, Pediatric Nephrology, vol.356, issue.3, pp.539-544, 2010.
DOI : 10.1007/s00467-009-1377-5

M. Kemper, J. Gellermann, and S. Habbig, Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome, Nephrology Dialysis Transplantation, vol.27, issue.5, pp.1910-1915, 2012.
DOI : 10.1093/ndt/gfr548

P. Ravani, A. Magnasco, and A. Edefonti, Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome: A Randomized Controlled Trial, Clinical Journal of the American Society of Nephrology, vol.6, issue.6, pp.1308-1315, 2011.
DOI : 10.2215/CJN.09421010

A. Sinha, A. Bagga, and A. Gulati, Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome, Pediatric Nephrology, vol.22, issue.2, pp.235-241, 2012.
DOI : 10.1007/s00467-011-1997-4

H. Franc¸ois, E. Daugas, and A. Bensman, Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological Considerations, American Journal of Kidney Diseases, vol.49, issue.1, pp.158-161, 2007.
DOI : 10.1053/j.ajkd.2006.10.015

A. Beco, I. Castro-ferreira, and L. Coentrao, Rituximab for steroiddependent nephrotic syndrome, Clin Nephrol, vol.74, pp.308-310, 2010.

N. Kurosu, H. Sugiura, and C. Iwasaki, Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome, Internal Medicine, vol.48, issue.21, pp.1901-1904, 2009.
DOI : 10.2169/internalmedicine.48.2435

E. Hoxha, R. Stahl, and S. Harendza, Rituximab in adult patients with immunosuppressive-dependent minimal change disease, Clinical Nephrology, vol.76, issue.08, pp.151-158, 2011.
DOI : 10.5414/CN107092

J. Dantal, E. Bigot, and W. Bogers, Effect of Plasma Protein Adsorption on Protein Excretion in Kidney-Transplant Recipients with Recurrent Nephrotic Syndrome, New England Journal of Medicine, vol.330, issue.1, pp.7-14, 1994.
DOI : 10.1056/NEJM199401063300102

M. Kemper, G. Wolf, and D. Muller-wiefel, Transmission of Glomerular Permeability Factor from a Mother to Her Child, New England Journal of Medicine, vol.344, issue.5, pp.386-387, 2001.
DOI : 10.1056/NEJM200102013440517

R. Shaloub, PATHOGENESIS OF LIPOID NEPHROSIS: A DISORDER OF T-CELL FUNCTION, The Lancet, vol.304, issue.7880, pp.556-560, 1974.
DOI : 10.1016/S0140-6736(74)91880-7

T. Takei and K. Nitta, Rituximab and minimal change nephrotic syndrome: a therapeutic option, Clinical and Experimental Nephrology, vol.117, issue.5 Pt1, pp.641-647, 2011.
DOI : 10.1007/s10157-011-0465-6

S. Bruneau and J. Dantal, New insights into the pathophysiology of idiopathic nephrotic syndrome, Clinical Immunology, vol.133, issue.1, pp.13-21, 2009.
DOI : 10.1016/j.clim.2009.03.532

A. Fornoni, J. Sageshima, and C. Wei, Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis, Science Translational Medicine, vol.3, issue.85, pp.85-131, 2011.
DOI : 10.1126/scitranslmed.3002231

G. Fernandez-fresnedo, A. Segarra, and E. González, Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis, Clinical Journal of the American Society of Nephrology, vol.4, issue.8, pp.1317-1323, 2009.
DOI : 10.2215/CJN.00570109

J. Kari, S. El-morshedy, and S. El-desoky, Rituximab for refractory cases of childhood nephrotic syndrome, Pediatric Nephrology, vol.44, issue.5, pp.733-737, 2011.
DOI : 10.1007/s00467-011-1778-0